In the realm of biomanufacturing, space-time yield (STY) is increasingly recognized as an essential metric for evaluating upstream process efficiency. STY facilitates the direct comparison of various ...

Moving away from fed-batch has significant sustainability and cost-saving benefits, according to industry working groups.

Biologics developers are caught in a paradox: demand for therapies is climbing, but the industry faces constant pressure to cut costs and move faster. For upstream process scientists, the challenge is ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...

Explore continuous processing and process intensification in biomanufacturing through hybrid models, workforce evolution, and ...